CAV1 and pulmonary fibrosis: CXCL10 was used to alleviate fibrosis disease, such as bleomycin-induced pulmonary bleomycin-induced pulmonary fibrosis (Tager et al., 2004), and p-Cav-1 was also reported to be key player in the process of fibrosis (Shihata et al., 2017).